Close Menu

NEW YORK – Axim Biotechnologies plans to use an assay developed by recently acquired Sapphire Biotech as a companion diagnostic for drugs in development that inhibit  quiescin sulfydryl oxidase 1 (QSOX1), a tumor-derived enzyme involved in metastasis. 

Initially, San Diego-based Axim expects to launch it as a tissue-based, immunohistochemistry test in mid-2021. By early 2022, the company, which is also developing analogs to a drug it has licensed from Arizona State University, expects to market a dipstick version of the assay using plasma samples.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.